Characterization of paclitaxel (Taxol) sensitivity in human glioma- and medulloblastoma-derived cell lines.
暂无分享,去创建一个
[1] M. Berger,et al. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Cairncross,et al. Chemotherapy for brain tumors. , 1998, Oncology.
[3] B. Monsarrat,et al. Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[4] M. Jordan,et al. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. , 1998, Current opinion in cell biology.
[5] H. Kim,et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] S. Fujimoto,et al. Mutation of the p53 gene in human astrocytic tumours correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anti-cancer agents. , 1998, British Journal of Cancer.
[7] G. Hudes,et al. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. , 1998, British Journal of Cancer.
[8] M. Chamberlain,et al. Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] E. Cazap,et al. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group. , 1997, Seminars in oncology.
[10] M. Kavallaris,et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. , 1997, The Journal of clinical investigation.
[11] T. Fojo,et al. Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization* , 1997, The Journal of Biological Chemistry.
[12] R. Bjerkvig,et al. Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. , 1997, British Journal of Cancer.
[13] L. Hu,et al. Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation. , 1997, International journal of radiation oncology, biology, physics.
[14] H. Parekh,et al. Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. , 1997, Biochemical pharmacology.
[15] C. Croce,et al. Bcl2 is the guardian of microtubule integrity. , 1997, Cancer research.
[16] E. Cazap,et al. Paclitaxel in platinum-resistant ovarian cancer patients , 1997 .
[17] D. Ludlum. The chloroethylnitrosoureas: sensitivity and resistance to cancer chemotherapy at the molecular level. , 1997, Cancer investigation.
[18] I. Christensen,et al. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. , 1997, British Journal of Cancer.
[19] R. Brown,et al. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. , 1996, Molecular pharmacology.
[20] John Calvin Reed,et al. Bcl-2 Targets the Protein Kinase Raf-1 to Mitochondria , 1996, Cell.
[21] S. Cole,et al. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. , 1996, Biochemical pharmacology.
[22] E. Partridge,et al. Comparison of combination therapy with paclitaxel Taxol® and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study , 1996, International Journal of Gynecologic Cancer.
[23] M. Berger,et al. Phase II study of paclitaxel in patients with recurrent malignant glioma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Wood Hl,et al. Taxol is active in platinum-resistant endometrial adenocarcinoma. , 1996 .
[25] V. Gekeler,et al. P-glycoprotein-associated resistance to taxol and taxotere and its reversal by dexniguldipine-HCl, dexverapamil-HCl, or cyclosporin A. , 1996, International journal of oncology.
[26] S. Schold,et al. -deoxyguanosine and Bcnu ′ -benzyl-2 6 O Treatment of Human Brain Tumor Xenografts with Updated Version Citing Articles E-mail Alerts Treatment of Human Brain Tumor Xenografts with 06-benzyl-2'-deoxyguanosine and Bcnu1 , 2013 .
[27] L. Neckers,et al. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. , 1996, Cancer research.
[28] M. Berger,et al. Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] G. de Sousa,et al. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. , 1996, Cancer research.
[30] P. Hoskins,et al. Taxol is active in platinum-resistant endometrial adenocarcinoma. , 1996, American journal of clinical oncology.
[31] R. Hájek,et al. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview. , 1996, Neoplasma.
[32] B. Monsarrat,et al. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. , 1996, Cancer research.
[33] P. Ravdin. Taxoids: effective agents in anthracycline-resistant breast cancer. , 1995, Seminars in oncology.
[34] P. Carbone,et al. Current Therapy in Hematology-Oncology , 1992, Annals of Internal Medicine.
[35] M. Chamberlain,et al. Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] H. Choy,et al. Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. , 1995, Journal of the National Cancer Institute.
[37] E. Lazarides,et al. Taxol-Induced Mitotic Block Triggers Rapid Onset of a p53-Independent Apoptotic Pathway , 1995, Molecular medicine.
[38] M. Dolan,et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. , 1995, Cancer research.
[39] M. Berger,et al. Contribution of O6‐methylguanine‐DNA methyltransferase to resistance to 1,3‐(2‐chloroethyl)‐1‐nitrosourea in human brain tumor‐derived cell lines , 1995, Molecular carcinogenesis.
[40] M. Berger,et al. Contribution of O6‐methylguanine‐DNA methyltransferase to monofunctional alkylating‐agent resistance in human brain tumor—derived cell lines , 1995, Molecular carcinogenesis.
[41] M. Gore,et al. Platinum-Taxol non-cross resistance in epithelial ovarian cancer. , 1995, British Journal of Cancer.
[42] D. Silbergeld,et al. In vitro assessment of Taxol for human glioblastoma: chemosensitivity and cellular locomotion , 1995, Anti-cancer drugs.
[43] P. V. van Zijl,et al. Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer. , 1995, European journal of cancer.
[44] M. Dolan,et al. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. , 1995, Progress in nucleic acid research and molecular biology.
[45] G. E. Keles,et al. Establishment and characterization of four human medulloblastoma-derived cell lines. , 1995, Oncology research.
[46] X. Yang,et al. P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. , 1995, Oncology research.
[47] B. Sikic,et al. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. , 1995, Oncology research.
[48] P. Burger,et al. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. , 1994, Cancer research.
[49] C. Lipschultz,et al. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. , 1993, British Journal of Cancer.
[50] L. Helson,et al. A saturation threshold for taxol cytotoxicity in human glial and neuroblastoma cells , 1993, Anti-cancer drugs.
[51] W. Mellado,et al. Taxol: Mechanisms of Action and Resistance a , 1986, Journal of the National Cancer Institute. Monographs.
[52] M. Christian,et al. Clinical development of Taxol. , 1993, Journal of the National Cancer Institute. Monographs.
[53] K. Weinberg,et al. Multidrug resistance gene expression in pediatric primitive neuroectodermal tumors of the central nervous system. , 1992, Journal of neurosurgery.
[54] H. Fessi,et al. Effects of free and liposome-encapsulated taxol on two brain tumors xenografted into nude mice. , 1992, In vivo.
[55] J. M. Ford,et al. Pharmacology of drugs that alter multidrug resistance in cancer. , 1990, Pharmacological reviews.
[56] D. Beranek. Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. , 1990, Mutation research.
[57] K. Wallner,et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. , 1989, International journal of radiation oncology, biology, physics.
[58] D. Dexter,et al. Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate. , 1988, Cancer research.
[59] V. Ling,et al. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies , 1985, Nature.
[60] V. Ling,et al. Reduced permeability in CHO cells as a mechanism of resistance to colchicine , 1974, Journal of cellular physiology.
[61] M. A. Everett,et al. The Biologic Effects of Ultraviolet Radiation , 1970 .
[62] J. Pontén,et al. Long term culture of normal and neoplastic human glia. , 2009, Acta pathologica et microbiologica Scandinavica.
[63] W. Walcher. [Chemotherapy of brain tumors]. , 1958, Der Krebsarzt.